RxDoctor Payments Data

Brett Bilbrey, MD

Family Medicine · Knoxville, TNNPI 1962448589

Payments from drug & device makers

$11,671in general payments, 2019–2025

Across 838 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • GSK$1K
  • Amgen$696
  • Boehringer Ingelheim$628
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$11,49699%
  • Education$1741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,671 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$103,658
Medicare patients
147
Services billed
5,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$143,955
EliquisApixaban101$101,587
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$65,237
Tresiba Flextouch U-200Insulin Degludec19$34,973
ShingrixVaricella-Zoster Ge/As01b/Pf114$26,136
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$25,798
Tresiba Flextouch U-100Insulin Degludec30$23,027
FarxigaDapagliflozin Propanediol17$21,705
Repatha SureclickEvolocumab19$18,991
XareltoRivaroxaban18$18,372
JardianceEmpagliflozin16$17,993
Breo ElliptaFluticasone/Vilanterol12$14,163
Gvoke Hypopen 2-PackGlucagon13$7,872
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$5,431
Albuterol Sulfate HfaAlbuterol Sulfate105$4,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,539$143,955138 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$1,309$105,536203 claims
PfizerEliquis$1,394$101,587101 claims
AstraZenecaFarxiga$436$21,70517 claims
Johnson & JohnsonXarelto$50$18,37218 claims
Boehringer IngelheimJardiance$628$17,99316 claims
Sanofi-aventis U.S. LLCLantus$92$1,11812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →